1.Diagnosis and treatment The patient Wang Mou, 32 years old, complained of 7 years of marriage without contraception and infertility in June 2010, her menstruation was irregular, 5-7/40-60 days, sometimes with progesterone to promote menstruation, menstruation in the middle, no dysmenorrhea. 25 years old, married, without contraception and infertility, she had been in an outside hospital and applied CC to promote ovulation for several cycles to guide the coitus and failed to conceive. Physical examination: T: 36.5℃, P: 80 beats/min, R: 20 beats/min, BP: 120/80mmHg. Height: 158cm, weight: 65kg, body mass index: 26.04. Neck and inner thighs were rough and pigmented, general condition was OK, mental status was OK, heart and lungs were OK, abdomen was soft and liver and spleen were not found; gynecological examination: vulva was developed normally, vagina was smooth, uterine body anterior to the uterus was smooth, vagina was smooth, uterine body anterior to the uterus was smooth, uterine body anterior to the uterus was smooth, uterine body anterior to the uterus was smooth. The cervix was smooth, the uterus was anteriorly positioned, normal size, no pressure pain, and no obvious abnormality in both adnexa. Auxiliary examination: 2010.6.2 on the 3rd day of menstruation, ultrasound: uterus size: 4.5×3.6×3.2cm, endometrium 1.0cm mass type, bilateral ovaries 0.2-0.5cm small follicles 15, basal endocrine suggests: FSH: 5.47mIU/ml, LH: 7.74mIU/ml, E2: 207.90pmol E2:207.90pmol/l,PRL:25.38ng/ml,INS:175Uiu/l, T:2.92nmol/l. TSH:1.4 mIU/ml. Husband’s semen routine was normal. Preliminary diagnosis: primary infertility, polycystic ovary syndrome. In 2010.9, bilateral tubal imaging showed that the uterine cavity was normal and both fallopian tubes were patent. Treatment: From 2010.6.2-8.30, the patient was given drospirenone ethinyl estradiol tablets and metformin to regulate the endocrine system for 3 cycles, and at the same time, the patient was advised to diet and do more aerobic exercise. 2010.8.30, the patient returned to the clinic on the 3rd day of menstruation, and her body weight had dropped to 63Kg, and the results of endocrine system suggested that the endocrine system showed that the endocrine system showed the following symptoms: FSH: 4.53 mIU/ml, LH: 4.71 mIU/ml, E2: 124.30 CC combined with HMG to promote ovulation, CC 1 capsule per day on the 3rd-7th day of menstruation, 2 injections (150IU) of HMG on the 8th and 10th day of menstruation, vaginal ultrasound on the 12th day of menstruation, follicles of the right ovary: 1.9cm1, follicles of the left ovary: 1.75cm1, urinary LH was positive, and HCG 10000IU was given to the patient. HCG 10000IU, instructed to cohabit on the 13th and 14th day of menstruation, vaginal ultrasound on the 15th day of menstruation showed: dominant follicle had been ovulated; routine luteal support. On the 17th day after ovulation, blood β-HCG: 532.0IU/L, suggesting biochemical pregnancy; continue luteal support. Vaginal ultrasound on the 35th day after ovulation suggested: intrauterine early pregnancy with a single fetus, gestational sac size: 2.7×2.5cm, fetal buds and fetal heartbeat were visible, and no abnormal echoes were detected in both adnexa. Ultrasound on the 84th day after menopause: gestational sac in the uterus, biparietal diameter: 2.2 cm, parietal hip length: 4.5 cm, good fetal heartbeat, placenta located in the anterior wall of the fundus, and no abnormality in the adnexa. 2.Discussion Heterogeneity of patients with polycystic ovary syndrome is obvious, symptoms, signs and symptoms of biochemical examination performance of a variety of patients in this case to obesity, insulin resistance as a characteristic, LH/FSH mildly increased, ovulation treatment emphasizes the importance of controlling body weight, the addition of insulin-sensitizing agent metformin, while with drospirenone ethinyl estradiol tablets, adjusting the menstrual cycle, and its anti-androgen and anti-salt corticosteroid activity so that the drug users without water sodium storage side effects. The anti-androgenic and anti-salt corticosteroid activity of the drug makes it possible to take the drug without the side effect of sodium storage. Ovulation induction therapy is still needed for those who have fertility requirements after pre-treatment. In terms of medication and because the patient has had CC to promote ovulation for a number of cycles failed to conceive. Therefore, CC and HMG combination therapy was used. Complementary to the side effects of a single drug, such as CC has a weak estrogenic and anti-estrogenic effect, and blood E2 competition with the hypothalamic E2 receptor, to promote the thalamus GnRH, pituitary FSH, LH secretion increase, stimulate follicular development, but the use of the drug after the rate of ovulation and pregnancy rate is low, the reason is that the drug luteal hypoplasia, the luteinization of the unruptured follicle syndrome (LUFS) occurs in high incidence of cervical mucus less viscous, unfavorable for sperm penetration, and the cervical mucus is not good for sperm. unfavorable for sperm penetration. The quality of cervical mucus is positively correlated with the dosage, the higher the dosage of CC, the poorer the quality of cervical mucus, and can directly affect the endometrial development. In this paper, the use of CC-HMG combined therapy significantly increased the ovulation rate and pregnancy rate. The quality of cervical mucus can be significantly improved. The effect of promoting ovulation and improving the fertilization rate is more significant. It is superior to the ovulation promotion therapy with CC alone.